Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mauna Kea Technologies SAS Announces Cellvizio Optical Biopsies Study Results


Thursday, 14 Mar 2013 12:45pm EDT 

Mauna Kea Technologies SAS announced a new study on the use of a Cellvizio optical biopsy to diagnose cancerous stomach tumors. The study was completed at the Soonchunhyang University Hospital Gastrointestinal Cancer Center in Seoul, Korea. Patients enrolled in the study underwent an optical biopsy prior to endoscopic resection of the cancerous tissue in the stomach lining previously diagnosed by endoscopic biopsy. The overall accuracy of the optical biopsy diagnosis was compared with endoscopic resection. The overall accuracy for the diagnosis of cancerous lesions in the stomach lining was 91.7% for optical biopsies and 85.2% for conventional biopsies. The combined accuracy of conventional endoscopic biopsies and optical biopsies was 98.1%. 

Company Quote

6.34
-0.16 -2.46%
11:35am EDT